IDEAS home Printed from
MyIDEAS: Log in (now much improved!) to save this article

Productivité de la recherche et rendements d'échelle dans le secteur pharmaceutique français

  • Nicolas Iung
  • Frédéric Rupprecht
Registered author(s):

    [eng] Research Productivity and Returns to Scale in the French Pharmaceutical Sector by Nicolas lung and Frederic Rupprecht This paper studies research productivity in French pharmaceutical laboratories. We measure the elasticities of the number of new products launched and the sales made by these products to the size of the laboratory launching them. Our study suggests that the development of new pharmaceutical products is subject to constant or decreasing returns and economies of scope. These economies could make it profitable for firms working in separate therapeutic fields to merge. Constant or decreasing returns also prevail in the discovery of blockbusters, but without economies of scope. However, this type of pharmaceutical product might be expected to show increasing returns due to the greater impact of researcher specialisation and the fixed costs associated with purchasing sophisticated equipment. [fre] Productivité de la recherche et rendements d'échelle dans le secteur pharmaceutique français par Nicolas lung et Frédéric Rupprecht On étudie dans cet article la productivité de la recherche pour les laboratoires pharmaceutiques français. Pour cela, on mesure les élasticités du nombre de spécialités nouvelles introduites par un laboratoire ainsi que des ventes réalisées par cette spécialité à la taille du laboratoire qui les met sur le marché. Notre étude suggère que la recherche pharmaceutique de produits nouveaux est soumise à des rendements constants ou décroissants mais aussi à des économies de gamme. Celles-ci peuvent rendre attrayantes des fusions entre firmes positionnées sur des classes thérapeutiques disjointes. Quant à la découverte de blockbusters, elle semble aussi régie par des rendements constants ou décroissants mais sans économies de gamme. Pourtant, on aurait pu s'attendre pour ce type de médicaments à la mise en évidence de rendements croissants résultants de la plus grande importance de la spécialisation des chercheurs et des coûts fixes liés à l'achat de matériel sophistiqué.

    If you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.

    File URL:
    Download Restriction: no

    File URL:
    Download Restriction: no

    Article provided by Programme National Persée in its journal Économie & prévision.

    Volume (Year): 135 (1998)
    Issue (Month): 4 ()
    Pages: 121-136

    in new window

    Handle: RePEc:prs:ecoprv:ecop_0249-4744_1998_num_135_4_5929
    Note: DOI:10.3406/ecop.1998.5929
    Contact details of provider: Web page:

    No references listed on IDEAS
    You can help add them by filling out this form.

    This item is not listed on Wikipedia, on a reading list or among the top items on IDEAS.

    When requesting a correction, please mention this item's handle: RePEc:prs:ecoprv:ecop_0249-4744_1998_num_135_4_5929. See general information about how to correct material in RePEc.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Equipe PERSEE)

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If references are entirely missing, you can add them using this form.

    If the full references list an item that is present in RePEc, but the system did not link to it, you can help with this form.

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your profile, as there may be some citations waiting for confirmation.

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    This information is provided to you by IDEAS at the Research Division of the Federal Reserve Bank of St. Louis using RePEc data.